The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes drug Ozempic to a rare eye disease.

Ozempic maker Novo Nordisk A/S is investing 8.5 billion kroner ($1.2 billion) to build a new major factory in Denmark to help meet growing demand for its blockbuster drugs.

Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday.

Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss drug Ozempic to include the reduction of kidney disease risk. The decision was based on findings of a trial,

The European Union’s drug regulator said it would review two studies that linked Novo Nordisk’s blockbuster diabetes drug Ozempic to a rare eye condition.

Denmark's drug regulator has asked the European Medicine Agency's safety committee to evaluate two studies that found a potential link between Novo Nordisk's (NVO) type 2 diabetes drug Ozempic (semaglutide) and a rare eye condition.